NNovo Nordisk Read More Novo Nordisk’s Blood Disorder Breakthrough Offers a Lifeline Amid GLP-1 Gloom2026-04-21 Novo Nordisk’s etavopivat succeeds in Phase 3 sickle cell trial, cutting painful crises by 27%. This diversifies its…